Hanger Inc

Hanger — Investor Presentation (August 2018)

39 slides from Hanger's investor presentation, Aug 22, 2018

  1. Slide 1: Cautionary Note Forward Looking Statements

    Cautionary Note Forward Looking Statements This presentation contains certain “forward-looking statements” relating to the Company. All statements, other than statements of historical fact included herein, are “forward looking statements.” These forward-looking statements are often identified by the

  2. Slide 2: Hanger At a Glance

    Hanger At a Glance Who We Are: Industry leader in orthotics and prosthetics (O&P) services $4.1 billion1 addressable O&P domestic U.S. market Pioneered prosthetic devices in 1861 Focus on custom devices By The Numbers (2017): Net Revenue $1.041 billion Adjusted EBITDA2 $120 million 4,600 employees i

  3. Slide 3: Hanger Values, Vision and Purpose

    Hanger Values,Visionand Purpose Our Values – Integrity, patient-focused, outcomes, collaboration, innovation – are the heartbeat of cultural evolution that places our patients at the core of everything do a we Our Vision - To lead the orthotic and prosthetic markets by providing superior patient car

  4. Slide 4: Business Mix

    Business Mix Primary Focusonthe Provision of Specialty Health Care 2017 Adjusted EBITDA1 2017 Hanger Net Revenue $119.6 million - 11.5% EBITDA margin $1.041 billion Patient Care $852.0 million Patient Care $148.0 million 81.9% revenue 17.4% margin Hanger Net Revenue Hanger Adjusted EBITDA1 G&A expen

  5. Slide 5: Investment Thesis

    Investment Thesis IndustryLeader With Multiple Strategic Advantages Market Leader SizeableMarket Differentiators GrowthLevers 1 2 3 4 The leading provider of orthotic and prosthetic services in the United States $4.1 billion market for prescription prostheses, orthoses and prefabricated/off-the-shel

  6. Slide 6: Discussion Agenda Points

    Discussion Agenda Points Our Market Patient Care Products & Services Focused Growth Strategy Financial Performance page 07

  7. Slide 7: Discussion Agenda Points

    Discussion Agenda Points Our Market Patient Care Products & Services Focused Growth Strategy Financial Performance page 08

  8. Slide 8: Orthotics and Prosthetics (O&P)

    Orthotics and Prosthetics (O&P) related Over 90% of Hanger’s revenue is to O&P Orthotics Orthotic devices modify the structural and functional characteristics of the neuromuscular and skeletal system Prescribed for injuries, musculoskeletal, neurological orthopedic disorders Prosthetics Prosthetic d

  9. Slide 9: Prosthetics: Large and Growing Addressable Market

    Prosthetics: Large and Growing Addressable Market Approximately 500,000 People Living with Major LimbLoss in the U.S. Disease 50% Trauma 47% Other 3% Approximately 350,000 people withmajor +90% arelower extremity limbloss utilize a prosthesis Typically havea3-5 year replacement cycle(70% recurring r

  10. Slide 10: O&P Market: Diverse Disease Mix Drives Demand

    O&P Market: Diverse Disease $4.1 State billion Mix Drives Demand Injuries – Approximately 76,000 major amputations per year, 5-10% of which are due to injury. +$1 billion spent on prosthetics secondary to injury $1,380 Endocrine &Circulatory –Endocrine and circulatory disorders drive the majority of

  11. Slide 11: Discussion Agenda Points

    Discussion Agenda Points Our Market Patient Care Products & Services Focused Growth Strategy Financial Performance page 012

  12. Slide 12: Patient Care Differentiators

    Patient Care Differentiators Building Sustainable Advantages in a Fragmented Industry National network and market leadership Patient Care1 $852.0 million 81.9% revenue Driving patient engagement, connectivity and satisfaction Hanger Net Revenue Products & Services Unique ability to measure and impro

  13. Slide 13: Scale as a Competitive Advantage

    Scale as a Competitive Advantage National Network Brings Hanger Closer to the Community Hanger Patient Care Clinics 800 Patient Care Locations 1 2 1,500 Clinicians certified, O&P clinicians in the U.S. 3 4 Hanger employs over 20% of the board Hanger is the only O&P provider operating a nationwide ne

  14. Slide 14: Market Leader in a Fragmented Industry

    Market Leader InaFragmented Industry O&P Patient Care Clinic Market (by location) Approximately 3,400 Clinics Hanger currently operates 789 Veterans Administration patient careclinics nationally patient care clinics satellite locations 15 next largest O&P providers 680 109 79 ranging from 14 - 26 cl

  15. Slide 15: Enhance Patient Engagement and Connectivity

    Patient Enhance Engagement and Connectivity Consistency, Quality of Patient Experience Programs andinitiatives toengage and connectour community, measure and improve patient satisfaction, driving retention and growth Clinicians and technicians connect with new amputees in the hospital at the time of

  16. Slide 16: Clinical Focus on Patient Outcomes

    Clinical Focus on Patient Outcomes Implementing Clinical Care StandardsandDemonstrating Value Clinical team and senior leadership Chief Clinical Officer and clinical leadership 1,500 certified / licensed clinicians 500 technicians and assistants Specialists and centers of excellence group Technology

  17. Slide 17: Revenue Cycle Management (RCM)

    Revenue Cycle Management (RCM) Central Function Drives Lower Disallowed Revenue Localized claims process Decentralized billing & collections. Industry bills under DMEPOS schedule pre-2015 Disallowed Revenue1: Peaks in million 2014 at $82 $ millions $90,000 $80,000 Disallowances peak in 2014 Payor do

  18. Slide 18: Enterprise Supply Chain

    Enterprise Supply Chain Opportunities to Leverage Buying Power andScale 11 3 2 4 Purchasing leverage Patient Care purchases 70% of materials for its own Manage COM Streamline inventory Hub andspoke fabrication Patient Care segment In addition to laboratories within local clinics, Hanger operates ele

  19. Slide 19: Discussion Agenda Points

    Discussion Agenda Points Our Market Patient Care Products & Services Focused Growth Strategy Financial Performance page 020

  20. Slide 20: Products and Services

    Products and Services NationalScale SupportsProfitableGrowth Products & Services1 $188.8 million 68% ofproducts & services net revenue derived from thedistribution ofO&P components and related devices through “SPS” 18.1% revenue Hanger Net Revenue Provides comprehensive catalog to independent O&P pr

  21. Slide 21: Discussion Agenda Points

    Discussion Agenda Points Our Market Patient Care Products & Services Focused Growth Strategy Financial Performance page 022

  22. Slide 22: Growth Strategy: Build a Durable and Scalable Platform

    Growth Strategy Build a Durable and ScalablePlatform Accomplishments: Stabilize and Invest G&A investment – leadership, infrastructure, technology Complete restatement of financials (May 2017) Current in SEC filings (June 2018) Operational initiatives Centralized revenue cycle management (RCM) Scale

  23. Slide 23: Growth Strategy: Accelerate to Growth

    Growth Strategy Accelerate to Growth Drive organic revenue growth via market share Drive to exceed industry growth rate of 1.5 - 2.0% Add clinicians Drive higher throughput and productivity Higher volume through referrals Focus on high-value customized devices 2 2015 - 2018 2019 - 2020 2020-Beyond p

  24. Slide 24: Growth Strategy: High Return M&A

    Growth Strategy High Return M&A Select, in-market acquisitions Disciplined approach to O&P acquisitions Focus on synergistic geographies and specialties Attractive valuations Full integration into centralized infrastructure offers incremental returns 2 2015 - 2018 2019 2020 - 2020-Beyond page 025

  25. Slide 25: Growth Strategy: Achieve Enhanced Scale

    Growth Strategy Achieve EnhancedScale Scalable platform Revenue growth consistently market High clinician utilization higher than G&A and supporting infrastructure costs relatively fixed, contributing margin expansion to gradual Cash flow yield grows 3 2015 - 2018 2019 - 2020 2020-Beyond page 026

  26. Slide 26: Discussion Agenda Points

    Discussion Agenda Points Our Market Patient Care Products & Services Focused Growth Strategy Financial Performance page 027

  27. Slide 27: Historical Performance: Net Revenue

    Historical Performance Annual andRecent Quarter Net Revenue $1,067.2 $1,042.1 $1,040.8 $1,012.1 2014 2015 2016 2017 Implemented claims documentation initiatives in 2016 to improve long-term revenue quality Return of growth to both segments in the second quarter of 2018 page 028 Year-to-date $497.1$5

  28. Slide 28: Historical Performance: Adjusted EBITDA

    Historical Performance EBITDA1 Annual andRecent Quarter Adjusted Second Quarter Year-to-date $119.6 $117.2 $115.2 $108.5 2014 2015 2016 2017 2017 Adjusted EBITDA improvement resulted primarily from lower disallowed revenue, personnel expenses and operating expenses in the Patient Care segment Produc

  29. Slide 29: Transformation Yields Same Clinic Results

    Transformation Yields AnnualandQuarterly Same Results Clinic Revenue PerDay %change1Quarter/Quarter change1 Year/Year Revenue impacted by claims documentation initiative 3.1% % Positive comps return in 2017 2.1% and 2018 3.5% -0.9% -3.1% Q1 2017 Q2 2017 Q3 2017 Q4 2017 Q1 2018 Q2 2018 2013 2014 2015

  30. Slide 30: Payor Mix and Accounts Receivables Trend

    Payor Mix and Accounts Receivables Trend Multi-Year Improvements in WorkingCapital Conversion Accounts Receivable, net (Orange Bars) $ millions Day Sales Outstanding (Black Line) Payor Mix, Percentage of 2017 Peak in late 2014 Patient Care Net Revenue $180,000 60 $170,000 16% 55 $160,000 50 $150,000

  31. Slide 31: Cash Flow, Liquidity and Capital Allocation Priorities

    Cash Flow, Liquidity and Capital Allocation Priorities Use Excess Cash Flow toExecute Growth Strategy DisciplinedCapital AllocationStrategy Flexible Balance Sheet2 StrongCash Flow Q2 2018 TTM Free Cash Flow (Adjusted $142.9 million comprised of: in liquidity, Re-invest in core systems and operating

  32. Slide 32: 2018 Outlook

    2018 Outlook GenerallyConsistent with 2017 Net Revenue and Adjusted EBITDA1 For the full year 2018, Hanger anticipates net revenue and Adjusted EBITDA to be generally consistent with actual 2017 results Net Incomeand Adjusted Net Earnings1 Hanger anticipates net share basis, as well as lower interes

  33. Slide 33: Investment Thesis

    Investment Thesis IndustryLeader With Multiple Strategic Advantages Market Leader SizeableMarket Differentiators GrowthLevers 1 2 3 4 The leading provider of orthotic and prosthetic services in the United States $4.1 billion market for prescription prostheses, orthoses and prefabricated/off-the-shel

  34. Slide 34: Appendix: Non-GAAP Reconciliations

    Appendix Non-GAAP Reconciliations

  35. Slide 35: Non-GAAP Reconciliations: Net Income to Adjusted EBITDA 2017-2014

    Non-GAAP Reconciliations Net Income to Adjusted EBITDA 2017-2014 For the Years Ended December 31, 2017 2016 2015 2014 Net loss - as reported (GAAP) Adjustments to calculate EBITDA : Depreciation and amortization Interest expense, net Extinguishment of debt $ (104,671) $ (106,471) $ (327,091) $ (18,9

  36. Slide 36: Non-GAAP Reconciliations: Segment Adjusted EBITDA

    Non-GAAP Reconciliations Segment, Adjusted Net Income Percentage to of EBITDA and AdjustedEBITDA For the Year Ended December 31, Margin as a Net Revenue2017 2017 Patient Care Net income (loss) - as reported (GAAP) Adjustments to calculate EBITDA: Depreciation and amortization Interest expense, net E

  37. Slide 37: Non-GAAP Reconciliations: Second Quarter 2018 v. 2017

    Non-GAAP Reconciliations Net Income to Adjusted EBITDA Second Quarter 2018 v.2017 Three Months Ended June 30, 2018 2017 Net income (loss) - as reported (GAAP) Adjustments to calculate EBITDA: Depreciation and amortization Interest expense, net Loss on extinguishment of debt $ 12,928 $ 1,637 9,272 7,

  38. Slide 38: Non-GAAP Reconciliations: Year-to-Date 2018 v. 2017

    Non-GAAP Reconciliations Net Income to Adjusted EBITDA Year-to-Date 2018 v. 2017 Six Months Ended June 30, 2018 2017 Net income (loss) - as reported (GAAP) Adjustments to calculate EBITDA: Depreciation and amortization Interest expense, net Loss on extinguishment of debt $ (9,690) $ (16,097) 18,602

  39. Slide 39: Non-GAAP Reconciliations

    Non-GAAP Reconciliations Net Income to Adjusted EBITDA Year-to-Date 2018 v. 2017 Six Months Ended June 30, 2018 2017 Net income (loss) - as reported (GAAP) $ (9,690) $ (16,097) Adjustments to calculate EBITDA: Depreciation and amortization 18,602 19,962 Interest expense, net 19,580 28,100 Loss on ex

Hanger — Investor Presentation (August 2018) on 6ix